** Shares of drugmaker Legend Biotech LEGN.O rise 29% to $33.15

** LEGN's experimental cell therapy shows early signs that its approach of generating disease-fighting cells within patients may work for a type of blood cancer

** In the early-stage trial, 12 patients with relapsed/refractory B-cell non-Hodgkin lymphoma were treated across two dose levels as of April 1

** The new therapy is designed to generate CAR-T cells directly within the patient through a single, direct infusion, eliminating the need for ex-vivo cell engineering and manufacturing

** In the higher-dose group, all six patients responded to treatment, including five who had no detectable signs of cancer, the company says

** Including session's moves, LEGN stock up 47% YTD